Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan
EV did not significantly impair renal function in patients with mUC. Comparable efficacy and safety were observed regardless of baseline eGFR, supporting the feasibility of EV in patients with impaired renal function.
Authors
- Toshio Takagi (ORCID: https://orcid.org/0000-0003-1775-0943)
- Toshihide Horiuchi
- Kazutaka Nakamura
- Yuki Kobari (ORCID: https://orcid.org/0000-0002-1407-2588)
- Kazuhiko Yoshida (ORCID: https://orcid.org/0000-0002-3834-0153)
- Tsunenori Kondo (ORCID: https://orcid.org/0000-0003-2228-4086)
- Hiroshi Kobayashi (ORCID: https://orcid.org/0000-0002-0748-3784)
- Junpei Iizuka
- Yasunobu Hashimoto
- Yuki Nemoto (ORCID: https://orcid.org/0000-0003-4290-0595)
- Shun Watanabe (ORCID: https://orcid.org/0000-0002-5529-7791)
- Hiroaki Shimmura
- Haruhiko Kondo
- Shinsuke Mizoguchi
- Makiko Ichioka
Institutions
- Tokyo Women's Medical University Hospital (JP)
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Fukushima Medical University Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17898
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00